Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

Recruiting now

Conditions studied: Meningoccocal Disease

In brief

This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.

Key facts

Study ID

NCT07379151

Run by

Serum Institute of India Pvt. Ltd.

People needed

450

Starts

2026-05-05

Expected to finish

2026-12-01

Last updated by the study team

2026-06-03

Who can join

Age: 7 and older, up to 36. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Written informed consent and assent (if applicable)

You may not qualify if…

• Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination
• Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study

Where it is running

• Centre pour le Développement des Vaccins du Mali, ex-Institut Marchoux, Ministry of Health, BP251 Bamako, Mali BP251 — Bamako, Mali (enrolling)
• Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia — Banjul, The Gambia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.